Status: Recruiting

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

Participants needed: 41

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 1, 2026Locations: 1

Eligibility criteria

Ability to understand and willingness to sign informed consent form prior to ini... [+22]

Pregnant or breastfeeding. [+20]

Status: Not yet recruiting

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

To find the best method of administering NK cells in patients with recurrent glioblastoma.

Participants needed: 36

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 12, 2026Locations: 1

Eligibility criteria

Male or female subjects aged ≥ 18 years. [+11]

Has received prior interstitial brachytherapy, implanted chemotherapy, or therap... [+21]

Status: Recruiting

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Participants needed: 30

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 29, 2026Locations: 1

Eligibility criteria

Participants must have histologically confirmed ccRCC that is metastatic or unre... [+18]

Presence of clinically significant ongoing Grade ≥ 2 toxicity unequivocally asso... [+23]

Status: Recruiting

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.

Participants needed: 39

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 16, 2026Locations: 1

Eligibility criteria

Participants must be 18 years or older. [+15]

Pregnant, breastfeeding, or expecting to conceive within the projected duration... [+19]